LENZ Therapeutics (LENZ) AI Stock Analysis

• Market Cap: $500.64M
• Dividend Yield: N/A
• Average Volume (3M): 947.85K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.19
• Revenue Growth: N/A
• EPS Growth: 70.19%
• Country: US
• Employees: 6
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.59
• Shares Outstanding: 31,289,968
• 10 Day Avg. Volume: 510,985
• 30 Day Avg. Volume: 947,852
• PEG Ratio: 0.15
• Price to Book (P/B): 3.01
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -10.26
• Enterprise Value/Market Cap: 2.25
• Enterprise Value/Revenue: 64.47
• Enterprise Value/Gross Profit: 65.07
• Enterprise Value/Ebitda: -17.22
• 1Y Price Target: $57.50
• Price Target Upside: 259.38% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 5
• EPS Forecast (FY): -2.82
• Revenue Forecast (FY): $52.26M

• Rating: 51 Neutral
• Price Target: $16.50 ▲(3.13% Upside)

The score is held back primarily by weak financial performance (large losses and continued cash burn) and a clearly bearish technical setup (price below all major moving averages with negative MACD). Offsetting these risks, the latest earnings call was notably positive with FDA approval, strong early prescription metrics, and a substantial cash position to support the launch. Valuation remains constrained by negative earnings and no dividend support.

Positive Factors

Regulatory Progress

Regulatory progress without significant issues positions LENZ well for FDA approval, enhancing its ability to bring LNZ100 to market and capture market share.

Strong Financial Position

A robust cash position provides LENZ with the financial runway necessary to support its pre-launch activities and strategic initiatives, reducing liquidity risks.

Intellectual Property Strength

A strong patent portfolio protects LENZ's innovations, ensuring competitive advantage and potential market exclusivity until at least 2044.

Negative Factors

Persistent Financial Losses

Ongoing financial losses highlight operational challenges, affecting LENZ's ability to achieve profitability and requiring strategic pivots for sustainable growth.

Delayed Product Availability

Delays in product availability post-approval could hinder revenue generation and market penetration, impacting LENZ's growth trajectory.

Increased Operating Expenses

Rising operating expenses due to increased headcount and pre-launch activities may pressure margins, necessitating efficient cost management.

LENZ Therapeutics Business Overview & Revenue Model

Company Description

LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.

How the Company Makes Money

LENZ Therapeutics makes money primarily through the development and commercialization of its pharmaceutical products designed to treat eye diseases. The company generates revenue by advancing its drug candidates through clinical trials, obtaining regulatory approvals, and subsequently marketing these drugs to healthcare providers and patients. Additionally, LENZ may engage in strategic partnerships or licensing agreements with other pharmaceutical companies, which can provide upfront payments, milestone payments, and royalties based on product sales. These collaborations can significantly contribute to the company's earnings, allowing LENZ to leverage external resources and market reach while focusing on its core research and development activities.

LENZ Therapeutics Financial Statement Overview

Summary

LENZ Therapeutics faces significant financial challenges, including persistent losses and negative cash flows, despite a strong equity position and minimal leverage. The biotechnology industry is inherently high-risk, and LENZ's current financial trajectory highlights the need for strategic pivots to achieve profitability and sustainable growth. Investors should be cautious, considering the ongoing financial instability and liquidity risks.

Income Statement

The income statement reflects a challenging financial landscape for LENZ Therapeutics, as evidenced by consistent net losses and negative EBIT and EBITDA over multiple reporting periods. The absence of total revenue in recent periods signifies a lack of operational income, while net income remains negative, indicating sustained unprofitability. The firm's gross profit margin is also negative, further highlighting financial difficulties. These factors collectively illustrate significant financial hurdles.

Balance Sheet

LENZ Therapeutics shows a strong equity position, with stockholders' equity accounting for a significant portion of its total assets, resulting in a healthy equity ratio. The debt-to-equity ratio is low, indicating minimal leverage and financial risk. While the company maintains substantial cash reserves, the consistent negative net income affects the return on equity. Overall, the balance sheet displays financial stability but is challenged by profitability concerns.

Cash Flow

The cash flow statement reveals significant cash outflows from operating activities, indicating operational challenges. Although financing activities have provided cash inflows, these are not yet translating into positive free cash flow or net income. The negative free cash flow growth rate suggests ongoing operational cash demands, while the operating cash flow to net income ratio reflects insufficient cash generation relative to net losses. These factors underscore liquidity concerns and the need for improved cash management.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	17.50M	0.00	0.00	15.00M	0.00	0.00
Gross Profit	17.34M	-58.00K	0.00	15.00M	-734.00K	-121.00K
EBITDA	-65.51M	-49.71M	-72.41M	-10.47M	-70.03M	-68.21M
Net Income	-58.88M	-49.77M	-69.97M	-10.81M	-70.76M	-68.37M
Balance Sheet
Total Assets	210.70M	215.30M	70.38M	46.95M	18.34M	22.56M
Cash, Cash Equivalents and Short-Term Investments	202.17M	209.03M	65.79M	44.44M	18.31M	19.82M
Total Debt	461.00K	1.38M	329.00K	250.00K	0.00	0.00
Total Liabilities	16.78M	11.22M	163.09M	71.12M	32.55M	32.36M
Stockholders Equity	193.93M	204.08M	-92.71M	-24.17M	-14.21M	-9.80M
Cash Flow
Free Cash Flow	-46.16M	-59.86M	-60.41M	-94.57M	-58.59M	-10.27M
Operating Cash Flow	-45.22M	-59.39M	-60.38M	-87.98M	-52.85M	-8.72M
Investing Cash Flow	2.28M	-154.48M	-29.62M	-241.86M	-5.74M	-1.54M
Financing Cash Flow	27.18M	199.00M	80.70M	597.00K	417.47M	30.08M

LENZ Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 16.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LENZ, the sentiment is Negative. The current price of 16 is below the 20-day moving average (MA) of 19.69, below the 50-day MA of 24.82, and below the 200-day MA of 30.78, indicating a bearish trend. The MACD of -3.08 indicates Negative momentum. The RSI at 26.31 is Positive, neither overbought nor oversold. The STOCH value of 10.90 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for LENZ.

LENZ Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
STOK	70 Outperform	$1.76B	46.83	15.02%	―	1128.17%	―
CVAC	70 Outperform	$1.05B	6.50	17.68%	―	-86.40%	30.72%
SNDX	56 Neutral	$1.85B	―	-129.32%	―	597.19%	0.45%
RAPP	55 Neutral	$1.34B	-10.44	-23.41%	―	―	-37.07%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
LENZ	51 Neutral	$500.64M	-7.59	-28.78%	―	―	70.19%

LENZ Therapeutics Corporate Events

LENZ Therapeutics Responds to FDA Adverse Event Report

LENZ Therapeutics, Inc. addressed a recent adverse event report submitted to the FDA’s database regarding a retinal tear in a patient using VIZZ™. The patient had pre-existing retinal conditions, and independent specialists noted multiple risk factors, making a causal link to VIZZ uncertain. The company emphasized that this initial report does not change their safety expectations for VIZZ as such events may naturally occur, and they plan not to provide detailed case reports for future individual incidents.

The most recent analyst rating on (LENZ) stock is a Buy with a $52.00 price target. To see the full list of analyst forecasts on LENZ Therapeutics stock, see the LENZ Stock Forecast page.

LENZ Therapeutics Raises $80M Through Stock Sale

On October 7, 2025, LENZ Therapeutics sold 1,748,634 shares of common stock at $45.75 per share, generating approximately $80 million in gross proceeds. This transaction was conducted under the company’s ‘at the market’ Sales Agreement with TD Securities (USA) LLC, highlighting a significant capital-raising effort that could impact the company’s financial strategy and market positioning.

The most recent analyst rating on (LENZ) stock is a Buy with a $53.00 price target. To see the full list of analyst forecasts on LENZ Therapeutics stock, see the LENZ Stock Forecast page.